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TI{E MODE OF ACTION OF HEPARINS IN VITRO AND IN VIVO
H.C. Hemker and S. Bdguin
Department of Biochemistry, Cardiovascular
Research Institute and University of Limburg
Maastricht, the Netherlands
The antithrombotic action of a heparin is not necessarily confined to its effects on
the clotting mechanism. Yet we restrict ourselves here to a discussion of the action of
heparin on thrombin generation in platelet poor and platelet rich plasma for two reasons.
In the first place it is more likely than not that inhibition of the clotting mechanism is at
least one of the major working arms of heparin. All medication that inhibits blood
clotting has an antithrombotic effect and all dis-orders that are known to impede clotting
inhibition are accompanied by a thrombotic syndrome. Also the assumption that heparins
act through their interference with blood coagulation is tacitly at the basis of vinually all
studies of the pharmacokinetics and pharmacodynamics of heparin action, both clinical
and experimental. Finally it is the subject that we studied and the only one that we dare
to express ourselves about.
SPECIFIC AND COMPOSITE EFFECTS
Thd actions of heparin on haemostasis and thrombosis can be devided in specific
biochemical effects, that are the effects on those biochemical processes that are at the
basis of the action of heparin, and composite biological effects that are the consequence
of the specific effects acting in some biological system, either in vivo or in vitro. The
specific effects are: Increasing thrombin activation; increasing the activation of factor
Xa; increasing the activation of factor IXa (1). There are good grounds to think that
inactivation of other cloning factors is of no practical importance. All these activations
take place through binding of heparin to antithrombin trI (AT III). The action of heparin
on thrombin via heparin cofactor II (HC II) occurs at such high concentrations of
heparin as are seldomly obtained in clinical practice and will not be subject of
discussion (2). Other negatively charged polyelectrolytes such as pentosan polysulfate
(3) and lactobionic acid (4) do act via HC II, but they are not subject of this article.
The composite biological effects of heparin on the haemostatic-thrombotic
apparatus are many and varied. The main ones are: The antithrombotic effect and the
haemorrhagic effect. In fact these two are the only ones that matter if our aim is to find
a good antithrombotic drug. They need extensive, laborious clinical experimentation to
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be determined, so it is logical that we resource to model systems in order to find
indications on these effects by laboratory shortcuts. They come in two kinds:
determination of antithrombotic and haemorrhagic effects in animals and measurements
of other composite effects on (human) blood or plasma.
The biological effects observed in the laboratory on isolated blood or plasma,
either platelet poor (PPP) or platelet rich (PRP), again come in a great many varieties.
Many of them are a variation on the clotting times, such as the activated pafiial
thromboplastin time (APfi) or the Heptest. A clouing time is essentially the time that is
necessary for a threshold amount of thrombin (around 15 nM) to be formed. This means
that it is especially sensitive to influence on the lag phase of thrombin formation, where
thrombin mediated feedback activation of factor VtrI takes an especially important
place. That is why tests like the APTT, where factor VItra formation is a rate limiting
step in the lag phase, are sensitive to the action of heparins (fig.l). The prothrombin
time (PT), where factor VIIIa does not play a role, is much less, if at all, affected
(fie.2). ,
Our studies since 1985 focussed our attention on an essentially different type of
biological effect. We determined the entire course of the thrombin generation curve
under the influence of heparin (5,6). These curves yield a wealth of information on the
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Figure 1. Thrombin generation in plasma (inrinsic system) inhibit€d by heparin. Methods as in ref. 6 with
adaptation of the incubation times of the sample and the chromogenic substrate to the levels of thrombin.
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Figure 2. Thrombin generation in Plasma (extrinsic system) inhibited by heparin. Methods as in ref.6 with
adaptation of tlre incubadon times of the sample and the chromogenic substrate to the levels of thrombin.
mode of action of heparins, particularly because they allow to separate the effect of
heparin on prothrombin conversion (thrombin generation without thrombin decay effects)
from that on thrombin inactivation (7). For practical everyday use outside the research
laboratory they are much too elaborate however. Reasoning that the action of the
enzyme thrombin will be proportional to its concentration and to the time that it is
allowed to act we determined the product of time and concentration, i.e. the area under
the thrombin generation curve, i.e. the time-concentration integral of thrombin generated
in clotting plasma, which we called the thrombin potential.-we also found a way to
determine the thrombin potential in a one-stage spectrophotometric procedure (g).
Any of the composite effects is a complicated function of the ensemble of the
specific effects. The example of the APTT and the PT already shows that even in one
class of composite effects the sensitivities for the specific effecis may differ enormously.
There is no a priori reason to assume that any one composite or specific effect will be a
good yardstick for the antithrombotic- or antihaemostatic action of a heparin. yet the
observation that all anticoagulant drugs invariably are a) antithrombotic, in a dose
dependent way, b) antihaemostatic when overdosed, and c) decrease the thrombin
potential in a dose dependent way, whereas clotting times do not show such a systematic
variation, made us think that the thrombin potential may be a good model for the
antithrombotic potency of an anticoagulant drug.
HOW TO CI{ARACTERISE A HEPARIN
The specific effects are well defined biochemical propefties whereas the biological
effects are unknown functions of the specific effects. Fiom this consideration it foliows
that a heparin should be characterised by its specific effects rather than by its biological
ones. Unfornrnately a biological effect, and a rather bizane one viz. the prolongation of
the prothrombin time of goat plasma, has been chosen to define the pharmacopea unit of
heparin activity. Here we will propose a fundamentally different approach that allows to
express heparin activity in standard-independent units of activity-and to determine the
levels of functional heparin in plasma.
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Figure 3. The HAM content and the HAM-specific activity of a series of LMWHs. o-o HAM
content; C..'."'a specific antittuombin activity.
TI{E zuNCTIONAL IIETEROGENEITY OF I{EPARIN
In fact the definition of heparin activity as an ilbitrary composite activity did no
harm as long as the proportion of the specific activities were similar in the different
preparations that were to be compared. This was the case until the low molecular weight
heparins (LMWHs) appeared on the scene. In the LMWHs however the antifactor Xa
shifts independently from the antithrombin activity. At that moment one can imagine
that an infinite variety of different combinations of the antifactor Xa activity and the
antithrombin activity can result in the same composite effect on the prothrombin time in
goat plasma, so that the unit of heparin activity becomes essentially senseless.
With decreasing molecular weight, glycosaminoglycans loose their capacity to
caralyse the AT III dependent inhibition of thrombin (9-15). Barrowcliffe et al (loc.cit.),
and Thomas et al (loc.cit.) have shown that heparin fragments with a chainlength of 10-
1.8 monosaccharide units have a high antifactor Xa activity, and that a length of 20-22
saccharides is necessary for an activity against thrombin. Lane and coworkers (loc.cit.)
studied heparins of 8 to >18 monosaccharides and concluded that 18 units is the smal-
lest chainlength that will allow to potentiate the inactivation of thrombin by AT III,
whereas the activity against factor Xa was high in all fragments. From this it follows
that all the high affinity material (HAM) in a heparin has anti factor Xa acfivity,
whereas antithrombin activity is,only expressed in HAM above the critical chainlength
of 18 monosaccharides (ACLM)r. Below critical chainlength material (BCLM), in order
to be active, has to bind to AT trI, i.e. it has to contain minimally the AT Itr binding
pentasaccharide. It thus comprises HAM with a length of between 5 and 18 sugar units
i.e. a Mr of 1500 - 5400. Classical unfractionated heparin ([IFI]) hardly contains any
BCLM. That explains why, before the advent of low molecular weight heparins,
arbitrary units would suffice to indicate the potency of a heparin.
It has often been suggested that the smaller a heparin is, the more it exhibits an
anti-factor Xa activity. Apart from the fact that this per se is not true (see below) tttis
I In order to prevent long and awkward abbreviations we use ACLM (resp. BCLM) to
indicate Above (resp. Below) Critical chainl-ength hish dinity Material.
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rsually highly disperse LMWH prepararions 
.
rarin preparations the proportion of molecules
ases with decreasing mean molecular weight.
:f,:' Tfitr#hT.,;lffi ';ffihe ACLM
activities per amount of active material. 
H' with the purpose to determine the specific
7), was that the HAM content increases with
I fact that upon scission of a high_affinity
I III binding pentasaccharide increases witir
:hes 1002o in a pentasaccharide. We suspect that
activitvwithchain,,lrl:w;grero^re:#:1Jttr"T3""ff l;ff ll'Jr;ttr"'ltr'Ji
lnM. ?r far as they were related to facror Xa inhibirion *a p", 
"-"unt 
of ACLM forthrombin related phenomena. As a natural consequence the peak- and mean molecularweights of the active fraction in a LMWH will aiways u" rugt". than that of the totalheparin (fig.4).
TI{E SPECIFIC ACTIVITY OF A }IEPARIN
. 
The catalytic activities,of a heparin in the interaction beMeen AT III and thrombin(resp. factor Xa) can be used to quantitate its specific activity.
The reaction:
Heparin
Thrombin + AT III > Inactive product
under conditions occuring in clotting plasma is pseudo first order in thrombin. It is
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characterised by the half life time of thrombin (resp' F'Xa)' or' yhigh is the same thing'
Uy u J""uy .onrt''t, G.*"t that is inversely proportional- to the hatf life time' 
Upon
addition of heparin . ;fi"?; k6ou" increat". f-- its blank value (k56s)' pto,po,*o1l
to the concentraflons of AT Ifr iiTirepari" in the sample (B6guin et al. in press), hence:
kdr*y = kspec'[AT trI]'[heparin] + kut.nt
Any well designed anti-thrombin or anti-factor Xa activity gives a result that 
is
proportional to hecav. This value thus can be obtained from 
current laboratory tests if
adequate standards are available.
k,o" . is thespeci f ica 'c t iv i tyof thehepar in, i .e . theincreaseof thedecayconstant
that is brought uUoot ty ifre/o,,1 of heparin in the presence of l-IrM of AT Itr' 
It is
i;fl";;J Uj a) Ca** ions,'U) plasma proteins, c) ionic strength, pH,temperature erc" so
it should be determined under well defined, and specified conditions- The decrease 
of
IIAM content with Mr i" u lVfWff preparation is proportional to its molecular weight'
This explains most of the variation-of specific antifictor Xa activity with molecul-ar
weight. If antifactor Xa activity of a number of LMWHs is expressed pel pg of ACLM
is remarkably constant: (20.4 i 4.1 SIUArg, range 15'2 - ?6'8' n=11)(fig'3)' IIFH Td the
lst LMW standard are'excepuons: 39 t O'S Sru/pg' Thil 19y be due to a different
affinity to other plasma ptoteitts than that- of most other LMWHs'
From the auove ii wilt be clear that the simplest possible rational approach 
to
heparin standardisation is somewhat more complicated than alcepted 
practice at tttis
moment. This may be regretted but it may not be overlooked. one can not standardise
away the fact that LMWfrs have two different activities that cannot be measured 
with a
cornmon yardstick. A good example is the use of antifactor Xa units to compare 
the
potency of UFH and pJntasaccharide. One needs much more units of pentasaccharide to
achieve the same antithrombotic effect than of llFH (18). This does not mean that
pentasaccharide is a "bad" antithrombotic, but merely that it scores high on the
antifactor Xa scale and not at all on the antithrombin sCale, whereas the antithrombotic
effect is a composite effect that responds to boft antifactor Xa-and antithrombin 
specifrc
activity; but in fact better to the latter'
TIIEUSEoFSPECIFICACTIVITIESToDETERMINEPLASMALEVELS
When k-r" is known, *" 
,0u"*, observed in 
a plasma sample' can be used to
determine the 
-heparin 
concentratio"n"'iii tttut sample. After adequate standardisation the
results of anti-thrombin and anti-factor Xa tests thrn 
"un 
be expressed in terms of nglrnl
of functional hepann- Because all high affinity material (HAp.j. a LMWH catalyses
the inactivation of factor Xa, the anti-factor Xa activity will indicate the level 
of total
IIAM. The antithrombin activity will indicate the level of ACLM, i'e' the HAM with 
a
vr, t s+oo. BCLM, the betow critical chainlength materia! that catalyses factor 
Xa
inactivation only, can be obtained from the difference of HAM and ACLM' All LMWHs
in practical use are a mixture of ACLM a
pentasaccharide is a pure BCLM (19'20)'.'
LVrWrf via two specifrc activities: the antil
ACLM and the anti-factor Xa specific actir
the proportionallity with AT ltr, the AT tr
indepen-dently. If specific activities are to b
FC/ml) of ACLM and BCLM in Plasma sa
should be available.
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STANDARD INDEPENDANT UNTT OF HEPARTN ACTryITY
If one wants to short-circuit the two steps of first determining the specific activity
and then the heparin concenEation, o. *h"n working with insuffrciently defined
materials, one can always express heparin activity in termi of an unambi gaoui StandardIndependent Unit (SIU) of heparin activiry, that can be simply defined as that amount ofheparin that, when added to 1 ml of normal plasma, 
"oniuining 
lpM of AT Itr, will
raise the pseudo-first order decay constant of a clouing enzyme 
-by 
on" inverse minute.Standard materials can be defined in terms of SIU uniis. oi 
"o*r" 
there are two types
of sI units, that based on factor Xa inactivation (Xa-SIU) 
-J ,r,u, based on theinactivation of thrombin (IIa-SIU). Their use is not restricted to heparins, because one
can well define a thrombin based SI unit for dermatan sulfate, in that case reported onthe heparin cofactor II content. It will be clear that pentasaccharide activities can be
expressed in Xa-SI units and dermatan sulfates in Iia-SI units, but that heparins ingeneral will need to be expressed in both. Because of the functional andpharmacological heterogeneity of heparins it can be expected that the course of heparin
activity in vivo in terms of the two different units will not be identical (see below).
STANDARD UNITS AND STANDARD INDEPENDENT
UNITS, T}IE EFFECT OF CA++
A classical unit of standard heparin is an amount of heparin, e.g. 5 pg.
It has been automatically assumed to be a unit of antittronibin activ-ity as well as a unit
of antifactor Xa activity. In t9rm9 of activity one unir is far from being the same thinghowever. In fact one unit of the 4th international standad unit of heparin is a much more
active antithrombin than antifactor Xa agent, as is immediately seen when we express its
activity in standard independent units (table 1).
TABLE l. EQ{JTVALENCES OF STANDARD UNITS AND STANDARD
INDEPENDENT LINTTS
STAI\DARD AMoL]NT EQUrvALENT AMoIINT
IU-IIa IU-Xa SIU-IIa SIU-Xa
UFH
IJFH
LMWH
LMWH
LMWH
1 m g
I ru.  5.2 I  I
I mg 1000 67.0 168.0
1 IU-IIa 14.9 I 0.4
I IU-Xa 6.0 2.5 I
1000 193.0 193.0 r4.5 4.4
0.075
7.0 r.7
0.105 0.026
0.M2 0.010
There is still more confusion to be cleared. As a rule, in general laboratorypractice, it is common to deterrnine antithrombin and antifactor Xa actiwities in the
absence of Ca++ions- This is quite natural because the last thing one wants to have inthese decay experiments is to complicate them by the ri-ojt"n"oo, generation of
endogenous factor Xa or thrombin. If one designs experiments that attow te determi-
2 2 7
nation of decay constants in the presence of physiological amounts of Ca++, it appears
that the inhibition of factor Xa by standard unfractionated heparin is about twice as
efficient as in the absence of Ca++ (21). Low molecular weight heparins are hardly
affected by these concentrations of Ca++. So in the absence of Ca++, i.e. under the usual
laboratory conditions, the antithrombin activity of UFFI is significantly underestimated.
This makes that the current opinion about a high antifactor Xa over antithrombin ratio
of low molecular weight heparins is based on a laboratory artifact.
A SUMMARY OF PREVIOUS IN VITRO RESULTS
At different occasions we have given an overview of our previous results obtained
with PPP and PRP in vitro. The main conclusions are therefore only briefly summarised
here:
a) The main inhibitory action of UFH in clotting plasma is on thrombin. At
concentrations of UFH that inhibit almost completely the appearance of free thrombin,
the (extrinsic) conversion of prothrombin into thrombin is inhibited only 20-30 Vo. This
holds for the extrinsic system, where the secundary effects of inhibition of thrombin via
feedback mechanisms (see below) is not rate limiting (6).
b) Despite their reputedly high anti-factor Xa action also LMWHs act mainly
through inhibition of thrombin, unless they are so small as to have no antithrombin
action to speak of, i.e. pentasaccharide and other P-type heparins. In the terms proposed
in this article we must conclude that the P-type heparins that we recognised before
actually are those heparins that consist almost entfuely of BCL material (5,20).
c) The reason for a lack of a direct effect on prothrombin conversion despite a
definite anti-factor Xa action is that in clotting plasma, when enough procoagulant
phospholipid is added, factor Va is the rate limiting factor and factor Xa is present in
excess. Factor Xa levels must be lowered to less than 10 Vo of thek normal values
before this diminution shows up as a lack of saturation of phospholipid-adsorbed factor
Va, i.e. as an inhibition of prothrombinase (6,22).
d) In the intrinsic system factor VIIIa is rate limiting. Factor VIIIa generates as a
result of activation by thrombin. Inhibition of thrombin therefore inhibits the activation
of factor VIII and so, indirecdy the generation of factor Xa. Therefore, in the intrinsic
system, heparins inhibit prothrombin conversion via their antithrombin effect (6,23,24).
e) In platelet rich plasma without added procoagulant phospholipids, phospholipids
iue rate limiting. The burst of thrombin formation therefore occurs after traces of
thrombin have activated the platelets. Heparin will delay the burst because of its
antithrombin action. Activated platelets shed heparin-neutralising material (pf4). This
neutralises UFH to concentrations of up to 0.4 U/ml. LMWH partly escape this
inhibition (25).
AN APPROACH TO IN VIVO EFFECTS
In a preliminary experiment (26) we injected subcutaneously a dose of unfractiona-
ted heparin and of two kinds of LMWH ( 5000 U of UFH, 7500 Choay Units of
LMWH-A, 40 mg of LMWH-B). The fact that we only have data on one volunteer per
heparin precludes any quantitative conclusion. We present the results here only as a
proposal for a rational approach to LMWH pharmacology.
In our volunteers we determined the course of the heparin activity in the blood in
terms of SIUs and, via the specific activities, also the course of the blood levels of
ACLM and BCLM. Then we determined the main composite biological activities in the
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samples, i.e. the thrombin potential, the inhibition of the peak of facor Xa generation,the inhibition of the peak of prothrombin converting activiry and the thrombin potentialin platelet rich plasma.
The main conclusions are
a) UFlt causes no inhibition of prothrombinase and no inhibition in platelet richplasma' Both LMWHS cause some inhibition of prothrombinase and retain significantactivity in PRP.
b) ACLM from LIIWHs has a ronger half tife time than that of uFH. BCLM hasa longer half life time than ACLM from the same LMWH. This results in a ',fractiona-tion in.vivo" of the injected LMWH. Late samples are enriched in BCLM.
c) ACLM in all instances is the most active material. The biological activitiescorrelate much better with the ACLM content than with the BCLM content. Even theinhibition of the factor fu pr-t is primarily caused by the ACLM presenr. Evidentry bythe andfactor Xa activity of the ACLM,- because when e^presr.d in sl-units, i.e. in
ribition of factor Xa shows a correlation with
ractice the anti_factor Xa level will alwavs
if the anti-factor Xa action itself does ntt
rition of overall thrombin generation in pRp,
reflects the ract that ACLM is more ,""ri,i"?.d"f"l,lji1l",'ill"or""""lY#Xt1rfl:Jt'*
BCLM is.
It should once more be stressed that these are preliminary results that may indicatea trend but that are to be substantiated by more data.
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